We estimate the average time to generic entry upon obtaining FDA approval for the drug at 12 years based on a recent study by Grabowski et al. (2011). For sensitivity analysis, we employ a triangular distribution with endpoints of 10 and 14 years, respectively.
View full report
"rpt_antibacterials.pdf" (pdf, 1.43Mb)
Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®